Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

Exclusion criteria

• . NSCLC with histology containing any of the following: large cell neuroendocrine carcinoma, small cell lung cancer.
• . Primary tumor not deemed appropriate for surgical resection as assessed by treating surgeon.
• . Tumor with direct invasion of: mediastinum, diaphragm, heart, great vessels, trachea, esophagus, vertebral body, or carina.
• . Any other tumor characteristic making it not suitable for resection as determined by treating surgeon.
• . Any prior systemic therapy for index lung cancer, including immunotherapy, chemotherapy.
• . History of malignancy requiring systemic therapy within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death as assessed and confirmed by the study PI. (Patients with a history of stage I NSCLC treated with resection or radiotherapy are eligible for inclusion.)
• . Active or history of clinically significant autoimmune disease that, in the opinion of the investigator, could compromise the health and safety of the patient if treated with anti-PD1 immunotherapy. Notable exceptions include:
• . Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone.